Eli Lilly and Company $LLY Stock Position Lessened by Abner Herrman & Brock LLC

Abner Herrman & Brock LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,773 shares of the company’s stock after selling 1,027 shares during the quarter. Eli Lilly and Company makes up about 2.9% of Abner Herrman & Brock LLC’s holdings, making the stock its 9th biggest position. Abner Herrman & Brock LLC’s holdings in Eli Lilly and Company were worth $28,773,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the period. Bridgewater Advisors Inc. increased its position in Eli Lilly and Company by 0.3% in the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after acquiring an additional 11 shares during the period. Manske Wealth Management increased its position in Eli Lilly and Company by 2.5% in the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after acquiring an additional 11 shares during the period. Guardian Partners Inc. raised its stake in Eli Lilly and Company by 0.3% during the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock valued at $3,302,000 after acquiring an additional 12 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL raised its stake in Eli Lilly and Company by 1.6% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock valued at $565,000 after acquiring an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.3%

Shares of NYSE LLY opened at $905.30 on Friday. The stock has a market capitalization of $855.35 billion, a price-to-earnings ratio of 39.45, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a 50-day moving average price of $1,023.17 and a 200 day moving average price of $957.73. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period last year, the company posted $5.32 earnings per share. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Rothschild & Co Redburn boosted their target price on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a report on Monday, January 26th. Wolfe Research lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Morgan Stanley reissued an “overweight” rating and set a $1,313.00 price target on shares of Eli Lilly and Company in a report on Thursday, March 5th. Finally, The Goldman Sachs Group set a $1,260.00 price objective on Eli Lilly and Company in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,221.44.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: TRANSCEND‑T2D‑1 Phase 3: Lilly’s triple‑agonist retatrutide showed large A1C reductions and up to ~16.8% weight loss at 40 weeks — a potential blockbuster that expands Lilly’s obesity/diabetes franchise and supports long‑term revenue upside. Lilly PR Newswire
• Positive Sentiment: ADorable‑1 pediatric trial: Positive topline results for EBGLYSS in moderate‑to‑severe atopic dermatitis pediatric patients widen Lilly’s immunology pipeline and add another potential near‑term commercial opportunity. InsiderMonkey: ADorable‑1
• Positive Sentiment: High‑profile endorsement: Jim Cramer publicly said “buy” on Lilly, which can boost retail demand and sentiment in the near term. Yahoo Finance: Cramer
• Neutral Sentiment: Pipeline breadth: Lilly advanced non‑GLP‑1 programs (digital sleep tech in early Alzheimer’s, a new diabetes candidate in Japan, and a master IBD trial), which diversify long‑term growth but have limited immediate revenue impact. TipRanks: Digital Sleep Tech
• Negative Sentiment: Analyst downgrades and rating cuts: Recent downgrades (HSBC and others) have pressured sentiment and contributed to near‑term share weakness. AmericanBankingNews: Analyst Downgrade
• Negative Sentiment: Competitive and safety concerns: Novo Nordisk won FDA clearance for a higher‑dose Wegovy (raising competitive risk in obesity), and some reports flagged an unusual skin reaction/tolerability signal for retatrutide — both factors that can temper uptake forecasts and invite closer regulatory/physician scrutiny. Blockonomi: Wegovy dose Proactive: Retatrutide side‑effect note

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.